Abstract

Research Article

Effect of hemodialysis session on acute changes in inflammatory and cardiovascular risk biomarkers

Bernardo-Alio Lavín Gómez*, María-Teresa García Unzueta, Armando-Raúl Guerra Ruiz, Sonia Pérez San-Martín, Ana Berja, Natalia Fañanás Rodríguez, Sara Díez Espejo and Domingo González-Lamuño Leguina

Published: 09 January, 2020 | Volume 5 - Issue 1 | Pages: 004-010

Background: Inflammation is associated with enhanced cardiovascular risk profile and increased cardiovascular mortality in end-stage kidney disease patients undergoing hemodialysis. Mechanisms of activated acute phase reaction in patients on chronic hemodialysis remain to be identified. As successful treatment of the inflammatory condition in these patients may improve long-term survival, we studied potential changes in different inflammatory biomarkers of cardiovascular risk in end-stage kidney disease patients after a mid-week hemodialysis session.

Methods: Inflammatory biomarkers of cardiovascular risk (cystatin-C, homocysteine, C-reactive protein, procalcitonin, pentraxin-3, serum amyloid-A) and atherogenic plasma lipoproteins (Lipoprotein(a), cholesterol low and high density lipoproteins) were studied in 21 end-stage kidney disease patients previously and after a mid-week hemodialysis session.

Results: We found a significant reduction in serum levels of low molecular weight molecules: cystatin-C (5.56 to 1.85 mg/L, 66.73%, p < 0.001), homocysteine (22.85 to 13.25 µmol/L, 42.01%, p < 0.001) and procalcitonin (0.788 to 0.457 ng/mL, 42.01%, p < 0.001). Large molecules as C-reactive protein (9.70 to 9.90 mg/L, 2.06%, p = 0.022) and pentraxin-3 (1.67 to 4.28 ng/mL, 156%, p < 0.001) increased, but serum amyloid-A decreased (15.90 to 12.70 mg/L, 20.13%, p < 0.05). There was no change in Lipoprotein (a) levels.

Conclusion: Pentraxin-3 was a more specific inflammatory vascular marker than C-reactive protein, and the best inflammatory marker associated with hemodialysis. Homocysteine, procalcitonin and the other small proteins could be released and removed during hemodialysis session. Further studies are needed to understand the behavior and significance of these markers after successive hemodialysis.

Read Full Article HTML DOI: 10.29328/journal.jccm.1001077 Cite this Article Read Full Article PDF

Keywords:

Biological-markers; Hemodialysis; Inflammation; Pentraxin-3 protein; Procalcitonin; Serum amyloid-A

References

  1. Perk J, DeBacker G, Gohlke H, Graham I, Reiner Z, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012; 33: 1635–1701. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22698795
  2. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999; 55: 648-658. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9987089
  3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel-lII). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATPIII) final report. Circulation. 2002; 106: 3143-3421. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12485966
  4. Stone NJU, Robinson J, Lichtenstein AH, BaireyMerz CN, Blum CB, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63 (25 Pt B): 2889-2934. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24239923
  5. International Atherosclerosis Society (IAS) Harmonized guidelines on prevention os atherosclerotic cardiovascular diseases. 2003; http://www.athero.org/
  6. Inoue K, Kodama T, Daida H. Pentraxin 3: a Novel Biomarker for Inflammatory Cardiovascular Disease. Int J Vasc Med. 2012; 2012: 657025. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22347626
  7. Artl A, Marsche G, Sattler W, Malle E. Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler Thromb Vasc Biol. 2000; 20: 763-772. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10712402
  8. Eklund KK, Niemi K, Kovanen PT. Immune functions of serum amyloid A. Crit Rev Imunol. 2012; 32: 335-348. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23237509
  9. Belhadj-Tahar H, Coulais Y, Tafani M, Bouissou F. Procalcitonin implication in renal cell apoptosis induced by acute pyelonephritis in children. Infect Drug Resist. 2008; 1: 17-20. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21694876
  10. Lavín-Gómez BA, Palomar-Fontanet R, Gago-Fraile M, Quintanar-Lartundo JA, Gómez-Palomo E, et al. Inflammation markers, chronic kidney disease, and renal replacement therapy. Adv Perit Dial. 2011; 27: 33-37. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22073825
  11. Peralta CA, Jacobs DR, Katz R, Ix JH, Madero M, et al. Association of pulse pressure, arterial elasticity, and endothelial function with kidney function decline among adults with estimated GFR >60 mL/min/1.73 m2: The multi-ethnic study of atherosclerosis (MESA). Am J Kidney Dis. 2012; 59: 41-49. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22000727
  12. Keller T, Messow CM, Lubos E, Nicaud V, Wild PS, et al. Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the Athero Gene study. Eur Heart J. 2009; 30: 314-320. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19153178
  13. Malinowska J, Kolodziejczyk J, Olas B. The disturbance of hemostasis induced by hyperhomocysteinemia; the role of antioxidants. Acta Biochim Pol. 2012; 59: 185-194. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22577622
  14. Wierzbicki AS. Homocysteine and cardiovascular disease: a review of the evidence.Diab Vasc Dis Res. 2007; 4: 143-150. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17654449
  15. Gómez-Gerique JA, López-Martínez D, Cancelas P, Montoya MT, Porres A. Expresión fenotípica de la Lp(a) en niños y adolescentes españoles. Med Clin (Bar). 2000; 114: 13-15.
  16. Conti G, Amore A, Chiesa M, Mancuso D, Cirina P, et al. Procalcitonin as a marker of micro-inflammation in hemodialysis. J Nephrol. 2005; 18: 282–288. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16013016
  17. Rysz J, Banach M, Cialkowska-Rysz A, Stolarek R, Barylski M, et al. Blood serum levels of IL-2, IL-6, IL-8, TNF-alpha and IL-1beta in patients on maintenance hemodialysis. Cell Mol Immunol. 2006; 3: 151-154. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16696903
  18. Trimarchi H, Dicugno M, Muryan A, Lombi F, Iturbe L, et al. Pro-calcitonin and inflammation in chronichemodialysis. Medicina (Buenos Aires). 2013; 73: 411-416. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24152395
  19. Katopodis KP, Koliousi E, Gouva C, Balafa O, Bairaktari E, et al. Acute effect of heparin on lipid parameters in patients on renal replacement therapy. ASAIO J. 2007; 53: 46-49. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17237649
  20. Lamon-Fava S, Diffenderfer MR, Marcovina SM. Lipoprotein(a) metabolism. Curr Opin Lipidol. 2014; 25: 189-193. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24751932
  21. Maury CP, Teppo A, Eklund B, Ahonen J. Serum amyloid A protein: a sensitive indicator of renal allograft rejection in humans. Transplantation. 1983; 36: 501–504. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/6356513
  22. Rao M, Guo D, Perianayagam MC, Tighiouart H, Jaber BL, et al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2005; 45: 324-333. https://www.ncbi.nlm.nih.gov/pubmed/15685511
  23. Snaedal S1, Heimbürger O, Qureshi AR, Danielsson A, Wikström B, et al. Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival. Am J Kidney Dis. 2009, 53: 1024-1033. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19394732
  24. Meuwese CL1, Snaedal S, Halbesma N, Stenvinkel P, Dekker FW, et al. Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-alpha are similarly associated with survival in haemodialysis patients. Nephrol Dial Transplant. 2011; 26: 1313-1318. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20846939
  25. Boehme M, Kaehne F, Kuehne A, Bernhardt W, Schröder M, et al. Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease. Nephrol Dial Transplant. 2007; 22: 2224-2229. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17496115
  26. Cieslik P, Hrycek A. Long PTX3 in the light of its structure, mechanism of action and clinical implications. Autoinmmunity. 2012;45: 119-128. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21988562
  27. Xu Y, Ding X, Zou J, Liu Z, Jiang S, et al. Plasma pentraxin3 is associated with cardiovascular disease in hemodialysis patients. Ren Fail. 2011; 33: 998-1004. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22013933
  28. Tong M, Carrero JJ, Qureshi AR, Anderstam B, Heimbürger O, et al. Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol. 2007; 2: 889-897. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17702732
  29. Oldani S, Finazzi S, Botazzi B, Garlanda C, Baldassarre E, et al. Plasma pentraxin-3 as a marker of bioincompatibility in hemodialysis patients. J Nephrol. 2012; 25: 120-126. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21725917
  30. Sjöberg B, Qureshi AR, Anderstam B, Alvestrand A, Bárány P. Pentraxin 3, a sensitive early marker of hemodialysis-induced inflammation. Blood Purif. 2012; 34: 290-297. https://www.ncbi.nlm.nih.gov/pubmed/23235124
  31. Yamamoto T, Nascimiento MM, Hayashi SY, Qureshi AR, Waniewski J, et al. Changes in circulating biomarkers during a single hemodialysis session. Hemodial Int. 2013; 17: 59-66. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22716238
  32. Nagai K, Ueda A, Saito C, Zempo-Miyaki A, Yamagata K. Annual decline in pentraxin-3 is a risk of vascular access troubles in hemodialysis patients. Int J Nephrol. 2014; 2014: 297954. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25587447
  33. Hansson GK, Libby P, Schönbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002; 91: 281–291. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12193460
  34. Panichi V, Scatena A, Migliori M, Marchetti V, Paoletti S, et al. Biomarkers of Chronic Inflammatory State in Uremia and Cardiovascular Disease. Int J Inflam. 2012; 360147. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22701810
  35. Memoli B, Minutolo R, Bisesti V, Postiglione L, Conti A, et al. Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes. Am J Kidney Dis. 2002; 39: 266-273. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11840366
  36. Malaponte G, Libra M, Bevelacqua Y, Merito P, Fatuzzo P, et al. Inflammatory status in patients with chronic renal failure: The role of PTX3 and pro-inflammatory cytokines. Int Mol Med. 2007; 20: 471-481. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17786277
  37. Reis ES, DeAngelis RA, Chen H, Resuello RR, Ricklin D, Lambris JD. Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters. Immunobiology. 2015; 220: 476-482. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25468722

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?